Sage Therapeutics Inc. Stock
Sage Therapeutics Inc. Stock
With only a change of €0.005 (0.040%) the Sage Therapeutics Inc. price is nearly unchanged from yesterday.
Our community is currently high on Sage Therapeutics Inc. with 5 Buy predictions and 3 Sell predictions.
Based on the current price of 11.53 € the target price of 26 € shows a potential of 125.5% for Sage Therapeutics Inc. which would more than double the current price.
Criterium "Valuation (undervalued/overvalued)" is seen as the biggest plus for Sage Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sage Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | 0.040% | -7.586% | -20.370% | -70.585% | -39.700% | -79.833% | - |
| Ironwood Pharmaceuticals | 0.680% | 2.069% | -1.333% | -23.711% | -27.451% | -18.681% | - |
| Novocure Ltd | 3.290% | 25.795% | 13.841% | -76.180% | 1.121% | -90.875% | - |
| Iovance Biotherapeutics Inc. | -4.310% | 17.799% | 4.082% | 109.285% | 66.560% | -44.518% | - |
Comments
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
News
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
